Cambridge, United States
Harbour BioMed, operating under the slogan "Healthy Life · Breakthrough Medicines," is a dynamic player in the global biopharmaceutical landscape. Established in 2016, the company has rapidly developed a strong foundation in oncology and immunology through innovative antibody therapeutics.
This United States-headquartered company employs proprietary platforms like Harbour Mice® to create fully human monoclonal antibodies. Their unique ability to generate both two heavy and two light chain (H2L2) and heavy chain only (HCAb) antibodies sets them apart, especially through their HCAb-based immune cell engagers (HBICE®) known for outperforming traditional therapies.
Harbour BioMed recently secured a Post IPO Equity investment on 01 March 2025 from AstraZeneca, reflecting their growth potential and innovative capabilities. This investment solidifies their expansion efforts, positioning them strongly in the competitive Biopharma sector.
